List of Small Molecule Pharmaceuticals Companies in Denmark - 21

Albumedix is an England-based biotechnology company that manufactures and markets albumins for vaccine stabilization, cell and gene therapy applications.

At ALK, we go to work every day to make a difference for the many people with allergies around the world. It is our ambition to make life with allergy surprisingly simple for as many people as possible, and we build upon our strong heritage as a pioneer in allergy immunotherapy, when we continue to innovate, develop and market new products and solutions to help improve the health of people with allergies. Every day, our employees contribute to our aspiration of becoming the world leader in allergy by coming to work to do their best in the pursuit of providing new and better allergy treatments and solutions. We work in a high-energy, international setting where it is imperative that our people thrive and develop. Creativity, influence and opportunities are key elements in developing our people. ALK is a global company with production sites in Denmark, France, Spain and the United States. ALK was founded in Copenhagen in 1923 and today we employ around 2,900 people around the world. Our global headquarters is located in beautiful surroundings in Hørsholm, north of Copenhagen. Read more about ALK at www.alk.net

Eurofins Genomics was founded in 1990 and is part of the Eurofins Scientific Group, a Life Science Company with laboratories in 61 countries and 61,000 employees. We are an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis. Our services are tailored for pharma, diagnostics, agriculture, food, biotechnology and research applications worldwide. Imprint: https://www.eurofinsgenomics.eu/imprint/ Privacy Note: https://www.eurofinsgenomics.eu/privacy/

Cellari enables doctors and non-specialists to take full advantage of recent developments in artificial intelligence. Cellari aims to provide the most precise "active learning model" for biological image segmentation combined with an intuitive and easy-to-use user interface for carrying out complex image related tasks and analytics. An automated statistical testing service ensures statistical validity of clinical and research related results along with unparalleled review and methodology transparency functionalities. Cellari is a proud part of the InnoFounder – Graduate incubator for Cohort 5 of September 2019.

Draupnir Bio is a Danish biotechnology company driven by a deep commitment to scientific excellence and the desire to bring innovative therapies to patients in need. By harnessing the natural machinery of the lysosome, we are developing oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD), a rapidly emerging field that exploits a cell's own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. First-generation TPD approaches are exclusively limited to intracellular targets, leaving extracellular and membrane-bound proteins – 40% of the human proteome – untouched. At Draupnir, we are extending the potential of TPD to both extracellular and membrane-bound proteins in a pioneering approach using our novel and differentiated, proprietary technology platform which targets lysosome receptors and has the potential to revolutionise the field of TPD. Led by a highly experienced team of pharma and biotech industry leaders, Draupnir is a spin-out from Aarhus University, Denmark and the Max-Planck Society, Germany and is backed by a syndicate of leading European investors.

At Fertin Pharma we specialize in the development and manufacturing of oral and intra-oral dosage formats. Our mission – Supporting Healthier Living – is carried out through our continuous desire to create the most innovative and consumer-friendly consumer healthcare products in the market. With an innovative and global profile, we engage in successful partnerships with leading pharmaceutical & nutraceutical companies. Supported by an experienced Research & Development team, extensive expertise in sensory optimisation and advanced manufacturing facilities, we support our customers from product formulation development to testing, manufacturing and regulatory compliance in order to ensure a smooth market launch. With a history dating all the way back to 1915, we have accumulated vast expertise and know-how within the field of chewing gum and other delivery formats. This knowledge is the foundation of our company, and it supports our vision of being the world’s leading supplier of pleasurable and convenient oral delivery systems. Fertin is also focused on the advancement in the science of Nicotine. For this reason we have started the Nicotine Science Center, which contributes with scientific insight into nicotine and its delivery. Visit the Nicotine Science Center Website. Copy this link into your browser: www.nicotinesciencecenter.com

Fida Biosystems (Fidabio) offers a new proprietary technology developed for quantification and characterization of proteins and nanoparticles from 0.5 to 1,000 nm Dh, incl. antibodies, liposomes, exosomes, membrane embedded proteins et al. Based on accurate, in-solution, absolute measurements of hydrodynamic radius, the technology provides precise information about Kd, concentration, size, stoichiometry, conformational changes, oligomeric state, immunogenicity, multiple bindings etc. It is characterised by being fast (minutes), requiring very small sample amounts (ul-nl), and being exceptionally tolerant to the sample matrix, incl. plasma, serum, cell lysate, fermentation media etc. Contrary to most other procedures, the methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development are therefore avoided. I.e. the unique features of the FIDA technology enable characterisation and quantification in native (biorelevant) environments and in-built assay quality control and automation.

Kripthonite Therapeutics is a preclinical biotech company that develops a therapy that eliminates oxygen-depleted cancer cells in solid tumors. Oxygen-depletion heightens the most aggressive features of cancers and results in resistance towards radiation and immuno- and chemotherapy. Our therapy derails energy metabolism in oxygen-depleted cancer cells, leading to rapid and selective cancer cell killing.

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion. Disclaimer: This site is intended for discussions about LEO Pharma and the various initiatives LEO Pharma is involved in. Due to regulations, discussions about pharmaceutical products are not allowed on this site. All content must be factual and non-promotional. LEO Pharma reserves the right to moderate or remove any content that may be inconsistent with legislation, industry ethics and regulations and LEO Pharma’s values, including: - profane or vulgar language - insulting or offensive comments, such as displays of racism, calls to violence, hate propaganda, etc. - commercial or political advertising - copyright infringements, or any violation of the rights of external parties - automatically-generated content i.e. spam - wrong/false statements For more information about our social media principles, please visit https://www.leo-pharma.com/social-media-principles

Lophora is a clinical-stage CNS drug discovery company developing novel, next generation psychedelic medicines to treat a multitude of psychiatric disorders www.lophora.com Founded in 2018 Lophora has successfully finished initial characterization of its lead-candidate LPH-5 through funding granted by the BII (Novo Nordisk Foundation), public funds and experienced biotech investors. Lophora will initiate first-in-human trials by 2024. Efficacy of LPH-5 has been extensively characterized in vivo and has successfully completed GLP-Tox with expected CTA submission by Q2 2024.

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best.  The neuroscience market is on a growth trajectory. We see rapidly growing knowledge in the field, with many new exciting advances, expanded drugability as well as increased regulatory approvals. Brain disorders are sharply on the increase and the disease burden is growing. We are one of the only global pharmaceutical companies solely focused on the brain, and our research programs tackle some of the most complex challenges in neuroscience. Our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options. We work closely with patients, healthcare professionals and the neuroscience community to uncover causes and to find new treatments that can bring back quality of life to people living with brain disorders. Our ambition is to be #1 in Brain Health in the eyes of the patients we tirelessly serve. We are 5,400 employees in more than 50 countries. We have research facilities in Denmark and the United States, and our production facilities are located in Denmark, France, and Italy. Whether we work in labs, at desks or in the field, we are all tirelessly dedicated to restoring brain health. We build on our Danish heritage, fostering a culture of collaboration, responsibility and respect. Too many people worldwide live with brain diseases – complex conditions often invisible to others that nonetheless take a tremendous toll on individuals, families and societies. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions.

Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 and based in Copenhagen, Denmark. Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s. These disorders impact memory, movement, language, behavior and personality resulting in disability and death of millions of patients around the globe. We focus our groundbreaking science on identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases. Our name reflects this focus: Muna means ‘to remember’ in Old Norse.

Mission NMD Pharma is dedicated to developing novel treatments to improve muscle function and quality of life of patients with neuromuscular disease. Vision A future in which patients with neuromuscular disease live better and more independent lives. We have a unique translational muscle electrophysiology platform leveraging in-depth know-how of muscle physiology and muscular disorders for discovering and developing first-in-class therapeutics in neuromuscular diseases with a significant unmet medical need. NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia gravis. We have more than 25 employees with expertise in all areas of drug development. We are headquartered in Aarhus, Denmark, and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases. For more information, please visit the company website.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Ousia Pharma is a biotech spin-out from the University of Copenhagen developing novel peptide-drug conjugates for treatment of obesity and metabolic diseases. The company uses a proprietary targeting approach in which peptides are used to deliver modulators of synaptic plasticity to drive a potent and sustained weight loss without compromising safety. A main objective of Ousia Pharma is to advance the development of the lead weight loss drug candidate (OP-56) within general obesity.

PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) which specializes in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical ingredients (API) or intermediates in therapeutic products. It also produces a range of generic peptides and peptides used in cosmetics. The Group mainly serves pharmaceutical and biotech companies. By supporting its customers, PolyPeptide contributes to the health of millions of patients across the world. PolyPeptide provides its offering from pre-clinical through to commercial stages. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Established in 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. Find out more about our current vacancies at: https://polypeptide.teamtailor.com/

Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcome, increased morbidity, prolonged hospitalization and increased mortality. Our drug candidate SYN002 efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient. SYN002 highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.

Tailwind Biotech is a biotech company offering synthetic DNA design services for improved strain development. We use proprietary Artificial Intelligence to help bioproduction-based companies worldwide achieve more effective and more efficient genetic engineering processes. Our technology designs optimized DNA sequences that help to maximize biological manufacturing yields while reducing development costs. We believe that by leveraging the powerful mix of Artificial Intelligence and Synthetic Biology, we can accelerate advancements in healthcare, agriculture, sustainable energy and beyond.

VAR2 Pharmaceuticals is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications. We have a portfolio of proteins with unique affinity and specificity for these cancer-associated carbohydrates for the development of treatments for cancers where there is no effective therapy, such as sarcoma, triple negative breast cancers and prostate cancer. The technology is based on groundbreaking discoveries made by Ali Salanti and his group, at University of Copenhagen, in collaboration with Mads Daugaard at University of British Columbia. The board and management team have a proven track record of building successful biotechnology companies, and the Scientific Advisory Board is comprised of leaders who have a long track record of developing cancer drugs and early stage biotech companies.

Vesper Bio is a clinical stage biotech company and world leader in sortilin biology. Vesper's VES001 is being developed for Frontotemporal Dementia (FTD(GRN)) and is in phase IIa. VES001, is a patient friendly, first-in-class, brain penetrant, oral treatment which targets progranulin deficiency, a major underlying cause of frontotemporal dementia (FTD). As an orally delivered small molecule, VES001 is able to cross the blood-brain barrier and is an ideal dosing method among these patients due to their rapidly declining mental state. About frontotemporal dementia (FTD): Frontotemporal dementia (FTD), also known as frontotemporal lobar degeneration (FTLD), is a group of brain disorders that cause degeneration in the frontal and temporal lobes of the brain. FTD impacts a person’s behaviour, judgement, communication and ability to participate in all activities of daily living. It is the most common cause of dementia in people under the age of 60 and is often misdiagnosed as Alzheimer’s Disease. FTD(GRN) is a form of FTD caused by mutations of the progranulin gene (GRN), resulting in low progranulin levels. FTD(GRN) accounts for up to 12% of all FTD cases. There are thought to be around 17,400 patients with FTD(GRN) in the seven major markets and roughly 140,000 carriers at risk in these markets who will go on to develop FTD(GRN).

Zerion is a pharmaceutical company transforming the pharmaceutical landscape for formulation of poorly soluble drugs that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, we aim to develop new treatment options for patients across all small molecule therapy areas. We are focused on improving existing drug products by building an internal pipeline, while partnering with originators to enable their early stage drug molecules, striving to improve the lives of patients around the world.